0001209191-14-059087.txt : 20140922 0001209191-14-059087.hdr.sgml : 20140922 20140922192449 ACCESSION NUMBER: 0001209191-14-059087 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140919 FILED AS OF DATE: 20140922 DATE AS OF CHANGE: 20140922 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Horizon Pharma plc CENTRAL INDEX KEY: 0001492426 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 272179987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ADELAIDE CHAMBERS STREET 2: PETER STREET CITY: DUBLIN STATE: L2 ZIP: 8 BUSINESS PHONE: 011-353-1-649-8521 MAIL ADDRESS: STREET 1: ADELAIDE CHAMBERS STREET 2: PETER STREET CITY: DUBLIN STATE: L2 ZIP: 8 FORMER COMPANY: FORMER CONFORMED NAME: HORIZON PHARMA, INC. DATE OF NAME CHANGE: 20100520 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SMITH TODD N CENTRAL INDEX KEY: 0001523672 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35238 FILM NUMBER: 141114872 MAIL ADDRESS: STREET 1: 1033 SKOKIE BOULEVARD STREET 2: SUITE 355 CITY: NORTHBROOK STATE: IL ZIP: 60062 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2014-09-19 1 0001492426 Horizon Pharma plc HZNP 0001523672 SMITH TODD N C/O HORIZON PHARMA, INC. 520 EAST COOK ROAD, SUITE 520 DEERFIELD IL 60015 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2014-09-19 4 D 0 54138 D 0 D Stock Option (Right to Buy) 20.78 2014-09-19 4 D 0 18955 D 2020-12-20 Common Stock 18955 0 D Stock Option (Right to Buy) 4.96 2014-09-19 4 D 0 21880 D 2021-12-07 Common Stock 21880 0 D Restricted Stock Units 2014-09-19 4 D 0 6699 D Common Stock 6699 0 D Stock Option (Right to Buy) 2.40 2014-09-19 4 D 0 61000 D 2023-01-01 Common Stock 61000 0 D Restricted Stock Units 2014-09-19 4 D 0 41250 D Common Stock 41250 0 D Stock Option (Right to Buy) 7.61 2014-09-19 4 D 0 70000 D 2024-01-01 Common Stock 70000 0 D Restricted Stock Units 2014-09-19 4 D 0 62000 D Common Stock 62000 0 D Disposition in connection with the merger (the "Merger") contemplated by the Transaction Agreement and Plan of Merger among Horizon Pharma, Inc. (the "Issuer"), Vidara Therapeutics Holdings LLC, Horizon Pharma plc (formerly known as Vidara Therapeutics International Ltd.), Hamilton Holdings (USA), Inc. and Hamilton Merger Sub, Inc. Pursuant to the Merger, the outstanding securities of the Issuer are being canceled and automatically converted into securities of Horizon Pharma plc. The Reporting Person's acquisition of securities of Horizon Pharma plc in the Merger will be reported on a separate Form 4. 25% of the shares subject to the option vested on October 1, 2011, and the remaining shares vest in 36 equal monthly installments thereafter. In connection with the Merger, the stock option has been assumed and converted into options to purchase the same number of ordinary shares of Horizon Pharma plc at the same exercise price and on substantially the same terms. The stock option vests in 48 equal monthly installments following the date of grant. Each restricted stock unit represented a contingent right to receive one share of Horizon Pharma, Inc. common stock. Each restricted stock unit has been converted into a contingent right to receive one ordinary share of Horizon Pharma plc. The restricted stock units vest in four equal annual installments. /s/ Robert J. De Vaere, Attorney-in-Fact 2014-09-22